science

Study Finds Antidepressant Fluvoxamine May Alleviate Long COVID Fatigue

19 Temmuz 2026Science Daily

A recent clinical trial has revealed that fluvoxamine, a low-cost antidepressant, may significantly alleviate fatigue in individuals suffering from long COVID. Involving 399 participants, the study demonstrated that those taking fluvoxamine experienced improved quality of life compared to those receiving a placebo.
This finding marks a significant advancement in the treatment options available for long COVID-related fatigue.
Long COVID is a condition that affects many individuals who have recovered from COVID-19, with fatigue being one of the most prevalent and challenging symptoms. Current treatment options for long COVID are limited, making the discovery of effective therapies critical for improving patient outcomes.
The results of this study are particularly noteworthy as they suggest that a commonly used antidepressant can have broader therapeutic effects beyond mental health, potentially addressing the debilitating fatigue associated with long COVID. This could pave the way for new treatment protocols that integrate psychiatr…

NewsAI özeti

This article is for informational purposes only and should not be considered medical advice. Always consult a healthcare professional for medical concerns.